Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial

Michael, M; Groothoff, JW; Shasha-Lavsky, H; Lieske, JC; Frishberg, Y; Simkova, E; Sellier-Leclerc, AL; Devresse, A; Guebre-Egziabher, F; Bakkaloglu, SA; Mourani, C; Saqan, R; Singer, R; Willey, R; Habtemariam, B; Gansner, JM; Bhan, I; McGregor, T; Magen, D

Michael, M (通讯作者)，Baylor Coll Med, Texas Childrens Hosp, Dept Pediat, Div Pediat Nephrol, Houston, TX 77030 USA.

AMERICAN JOURNAL OF KIDNEY DISEASES, 2023; 81 (2): 145

Abstract

Rationale & Objective: Lumasiran reduces uri-nary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively pres......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索